LONDON (Reuters): GSK Plc said on Monday that its HIV-focused unit ViiV Healthcare’s cabotegravir injected drug and tablets got marketing authorisation from the European Medicines Agency.
Cabotegravir is recommended in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually-acquired HIV-1 infection in high-risk adults and adolescents weighing at least 35 kilogrammes, the company said.
